NTL Healthcare, a leading company in cervical cancer screening using artificial intelligence (AI), recently announced

the deployment of their AI cervical cancer screening system, CerviCARE AI, at the Federal University Hospital of São Paulo (UNIFESP) in Brazil.

This marks the beginning of their full-fledged entry into the Brazilian and Latin American markets.

 

Despite having relatively high medical standards in Latin America, Brazil ranks 3rd in the incidence rate and 4th in the mortality rate of cervical cancer among women

due to low early screening rates, with over 16,000 women diagnosed with cervical cancer each year.

 



Professor Neila Maria's team at the Federal University Hospital's Obstetrics and Gynecology department in São Paulo expressed hope that

the introduction of the CerviCARE AI, an AI cervical cancer screening system, will help establish an effective early screening system nationwide in Brazil

to reduce the high mortality rate of cervical cancer among Brazilian women. They anticipate that remote screening services will make a significant contribution

to healthcare in Brazil, particularly for women in rural areas with limited access to medical services.

 

According to Professor Neila Maria, CerviCARE AI is considered very useful for mass screenings due to its short and simple testing process.

They have initiated research on AI telecervicography combining real-time on-site analysis with telehealth service that allow for expert reading.

This research is being accelerated through the AI Global Voucher project under the supervision of Korea's Ministry of Science and ICT (NIPA).

 

Taehee Kim, CEO of NTL Healthcare, stated that the research findings will be presented at the Brazilian Society of Obstetrics and Gynecology congress

in Rio de Janeiro in November,showcasing the high accuracy and technological capabilities of CerviCARE AI to health authorities and medical professionals.

Currently, CerviCARE AI is being supplied in Brazil and Costa Rica, with plans to expand services to the entire high-cervical cancer incidence Latin American region soon.

 

CerviCARE AI was recently published in a Nature sister journal, Scientific Reports, under the theme of 'Improving Early Detection Rates of Cervical Cancer'.

The system rapidly analyzes cervical images in about 5 seconds (1) and distinguishes between normal and abnormal,

especially in the analysis of high-grade lesions of the cervix, showing remarkable results with a 98% sensitivity and 95.5% specificity (2).

 

 

 

Ref: 1) Test Report, Standard Bank, 2023

Ref: 2) Scientific Reports, 2024